Samsung Biologics reports Q4, 2021 fiscal year financial results

By The Science Advisory Board staff writers

January 25, 2022 -- Samsung Biologics reported strong financial results for the fourth quarter and record high earnings for the 2021 fiscal year, achieving fourth quarter revenue of 444.3 billion South Korean won ($37 million U.S.), an increase of 18% from 375.3 billion South Korean won ($31 billion U.S.) reported for the fourth quarter last year.

The company's fourth quarter 2021 operating profit was 128.8 billion South Korean won ($11 million U.S.), which was 39% higher than the prior year period. Meanwhile, the company's fourth quarter 2021 net profit reached 79.3 billion South Korean won ($66 million U.S.), a decrease of 16.9 billion South Korean won ($14.1 million U.S.) from 96.2 billion South Korean won ($77 million U.S.) in the fourth quarter a year ago. The fourth quarter 2021 operating margin was 29% due to increased utilization across all plants and improved product mix, Samsung said.

Samsung Biologics demonstrated strong operational and business agility in 2021 with its three manufacturing plants in stable operations, the firm said. With its mRNA business, it signed strategic partnership agreements with Moderna for fill and finish and Greenlight Biosciences for the manufacturing of mRNA vaccines. Samsung Biologics also launched its newest contract development organization process platform, S-Cellerate, for the development and commercialization of monoclonal antibodies.

GreenLight Biosciences, Samsung Biologics collaborate on COVID-19 mRNA vaccine manufacturing
Samsung Biologics will collaborate with GreenLight Biologics to manufacture an mRNA COVID-19 vaccine candidate at a commercial scale. The partnership...
Samsung Biologics to join carbon neutral initiative
Contract development and manufacturing organization Samsung Biologics has signed a memorandum of understanding to join the Frontier 1.5D initiative, which...
Samsung Biologics reports growth in Q2
New contracts and increased plant utilization propelled Samsung Biologics to a 34% increase in revenue in its second quarter.
Kineta, Samsung Biologics partner on solid-tumor therapy
Samsung Biologics has inked a deal providing end-to-end development and manufacturing services to advance Kineta's anti-V-domain immunoglobulin suppressor...

Copyright © 2022

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter